HIGHLIGHTS
SUMMARY
Given the indispensable role of tumor-infiltrating T_cells (TILs) in ICBs, little is known about how tumorintrinsic loss of IFN-γ signaling (IFNγR1KO) impacts TILs. JAK1/2 inhibition with Ruxolitinib selectively suppresses the growth of IFNγR1KO but not scrambled control melanomas, depending on T_cells and host TNF. ICBs, by blocking immune checkpoints (namely, CTLA-4, PD-1, and PD-L1) hijacked by tumor cells to evade immunosurveillance, enhance the effector function (e_g, IFN-γ production)15,16 and decrease the abundance of immunosuppressive FoxP3+ regulatory T_cells (Treg) in TILs17, leading to tumor rejection. Subsequently . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.